Risk factors for oral mucositis in patients with solid tumorsunder treatment with cetuximab: a retrospective cross-sectional study

Background: This study retrospectively analyzed the risk factors for oral mucositis (OM) during cetuximab treatment. Material and Methods: We screened patients using cetuximab and retrospectively evaluated the presence of OM based on medical records. We collected information from 2 years of evaluations. Patient medical records were reviewed to obtain data on chemotherapy cycle and dose, sex, age, primary tumor, TNM stage, and head and neck radiotherapy (HNR) history. The X2 test and multinomial logistic regression were used for statistical analysis (SPSS 20.0, p < 0.05). Results: Among 1831 patients, OM was showed in 750 in any grade (41%), during cetuximab treatment. Most patients were female (n=944, 51.6%), <70years-old (n=1149, 62.8%), had larynx cancer (n=789, 43.1%) in T4 (n=579, 47.7%), N0 (n=509, 52.6%) stages. Primary tumor surgery was performed in 1476 (80.6%) patients, radiotherapy in 606 (33.1%) patients and cetuximab protocols most used involved up to four cycles (n=1072, 58.5%) of <400mg (n=996, 54.4%) cetuximab doses. Female (OR [odds ratio] = 2.17, CI95% = 1.26-3.75), >70 years-old patients (OR = 16.02, CI95% = 11.99-21.41), with HHNR (OR = 1.84, 1.41-2.40), treated with >4 cycles (OR = 1.52, CI95% = 1.16-2.01) and high doses of cetuximab (OR = 3.80, CI95% = 2.52-5.71) are the greatest risk factors for OM. Conclusions: Since the clinical benefit of cetuximab in the treatment of older patients is limited and there is a high OM, especially in women with head and neck treated with radiotherapy, high doses and a high number of cetuximab cycles must be administered with caution. (AU)

Complicaciones gastrointestinales asociadas a quimioterapia de acondicionamiento para trasplante autólogo en pacientes con mieloma múltiple / Gastrointestinal complications associated with conditioning chemotherapy for autologous transplantation in patients with multiple mieloma

Objetivo: Determinar la prevalencia de mucositis oral (MO) y su gravedad en pacientes con mieloma múltiple (MM) sometidos a trasplante antólogo de sangre periférica (TASP) en nuestro centro. Otros objetivos son describir la duración de MO, utilización de Nutrición Parenteral Total (NPT) y analgesia, posibles infecciones y determinar la prevalencia de efectos adversos gastrointestinales (EA GI). Métodología: Estudio observacional, retrospectivo y longitudinal en pacientes con MM, sometidos a TASP acondicionado con melfalán a altas dosis. La variable principal estudiada fue la presencia de MO y su gravedad. Las variables secundarias fueron: duración de la MO, enfermedad peridontal previa (EPP), el tratamiento con NPT y con analgésicos y la presencia de infecciones. Resultados: Se incluyeron 34 pacientes en el estudio. El 71% (24/34) del total presentó MO y, de estos, el 42% (10/24) MO grave. El 38% (13/34) del total requirió de NPT, lo cual fue significativamente superior en el grupo de pacientes con MO grave (p<0,05). De los pacientes con MO, el 96% (23/24) requirió tratamiento analgésico sistémico. El 88% (30/34) y el 76% (26/34) del total, presentaron diarrea y náuseas y vómitos (N/V) respectivamente. Conclusiones: La MO tiene una alta prevalencia en los pacientes tratados con melfalán a dosis mieloablativas como acondicionamiento para TASP en nuestro hospital. La única variable que se relacionó con la presencia de MO fue la EPP. Otros EA GI que también tienen una alta prevalencia son la diarrea y N/V.(AU)

Objective: To determine the prevalence of oral mucositis (OM) and its severity in patients of multiple myeloma (MM) who had a procedure of autologous transplant of hematopoietic cells in our center. Other objectives are to describe the duration of MO, the use of Total Parenteral Nutrition (TPN) and analgesia, possible infections and determine the prevalence of gastrointestinal adverse effects (GI AE).Methodology: Observational, retrospective, and linear study of patients with multiple myeloma that went through conditioning myeloablative therapy and, after that, an autologous transplant of hematopoietic cells. Main variable was made the presence of OM and its duration. Secondary variables were OM degree, previous periodontal disease (PPD) parenteral nutrition and analgesic treatments and whether or not there was presence of infections. Results: 34 patients were included in the study. 71% (24/34) had OM and, among those, in 42% of cases (10/24) OM was severe. 38% (13/34) needed parenteral nutrition, with numbers significantly higher when it came to the ones affected by severe OM (p<0.05). 96% (23/24) of OM patients needed systemic analgesic therapy. 88% (30/34) and 76% (26/34) of all patients presented diarrhea and nausea and vomits, respectively. Conclusions: OM has a high prevalence in patients treated with Melphalan in myeloablative doses as a preparation for an autologous transplant of hematopoietic cells in our hospital. The only variable related to the presence of OM was previous mouth disease. More IG AE with high prevalence are diarrhea and nausea and vomits.(AU)

Manifestaciones bucales en cuidados paliativos: importancia, estrategias terapéuticas y su eficacia / Oral manifestations in palliative care: importance, therapeutic strategies and their effectiveness

Introducción y objetivo: En los cuidados paliativos, las afecciones de la boca son muy frecuentes e interfieren con la calidad de vida del paciente. La boca es un lugar que aún merece poca atención por parte de los profesionales de la salud. El objetivo del presente estudio es caracterizar los trastornos bucales en pacientes de cuidados paliativos, investigar estrategias farmacológicas y no farmacológicas y analizar su eficacia. Material y métodos: Estudio exploratorio, observacional y correlacional sobre trastornos bucales en pacientes hospitalizados en un servicio de cuidados paliativos en Portugal, entre el 6 de noviembre de 2019 y el 31 de julio de 2020. El instrumento de recolección de datos incluyó un cuestionario y consulta del expediente clínico de los enfermos. Resultados: En este estudio (n = 46), el grupo de edad más representativo fue el de 71-90 años (56,52 %). La mayoría presentaba enfermedad oncológica (84,78 %) y estaban polimedicados. De estos, el 95,65 % presentaba dentición incompleta, y el 41,30 % asumía que rara vez realizaba cuidados de higiene bucal. La xerostomía fue reportada por el 89,13 % de la muestra, se observó candidiasis bucal en el 76,09 %, lengua saburral en el 23,91 % y mucositis bucal en el 10,87 %. Los pacientes con patología oncológica están más predispuestos a las alteraciones bucales (p = 0,047) en comparación con los pacientes no oncológicos. Los pacientes con hábitos de higiene bucal frecuentes tienen menos trastornos bucales (rS = –0,54; p = 0,028). Hubo una mejora considerable en la lengua saburral con el aumento en la frecuencia del cuidado de la higiene bucal (p = 0,004). Conclusiones: La implementación de estrategias farmacológicas y no farmacológicas desempeña un papel central en el bienestar y calidad de vida de la persona. Es fundamental que los profesionales de la salud conozcan las afecciones bucales y sus síntomas, lo cual es fundamental para la promoción de su bienestar. (AU)

Introduction and objectives: In palliative care, there are many mouth disorders that arise, interfering with the patient’s quality of life. The mouth is a place that still deserves little attention by health professionals. The present study aimed to characterize mouth disorders in palliative care patients; to identify the etiology of mouth disorders; to investigate pharmacological and non-pharmacological strategies, and to analyse its efficacy. Materials and methods: an exploratory, observational and correlational study on the mouth disorders of patients hospitalized in a palliative care service in Portugal between November 6, 2019 and July 31, 2020. The data collection instrument included a questionnaire and the consultation of the patient’s clinical file. Results: In this study (n = 46), the most representative age group was from 71 to 90 years (56.52 %). Most of them had oncological disease (84.78 %) and were polymedicated. Of these, 95.65 % had incomplete dentition and 41.30 % rarely performed oral hygiene care. Xerostomia was reported by 89.13 % of the sample; oral candidiasis was found in 76.09 %; tongue coating in 23.91 %, and oral mucositis in 10.87 %. Patients with oncological pathology were more predisposed to mouth disorders (p = 0.047) when compared to non-cancer patients. Patients with frequent oral hygiene habits had fewer mouth disorders (rS = –0.54; p = 0.028). There was considerable improvement in tongue coating with increased frequency of oral hygiene care (p = 0.004). Conclusions: The implementation of pharmacological and non-pharmacological strategies plays a central role in patient comfort and quality of life. It is essential that health professionals are aware of mouth conditions and their symptoms, this being essential for the promotion of well-being. (AU)

Treatment of recurrent aphtous stomatitis: A systematic review

Background: Recurrent Aphtous Stomatitis (RAS) is the most common process affecting the oral mucosa. It is painful, multifactorial and generally recurrent. The aim of this systematic review is to know the last treatment approaches and their effectivity. Material and methods: we compared the outcome of different kind of treatments in terms of the improvement of the lesions, reduction of the size of those lesions and the time needed for their healing. Inclusion criteria were: clinical trials, articles written in English or Spanish and published less than 5 years ago. Results: we used the following keywords: "treatment", "aphtous stomatitis", "canker sores"; combined with Boolean operators AND y OR. We selected 28 articles for reading the whole text, and after applying the eligibility criteria, we selected 17 articles for our revision. Among all the treatments, we emphasize the barrier method based in compound of cellulose rubber and a calcium/sodium copolymer PVM/MA, with which the difference in the 3rd and 7th day was of -6,29 ± 0,14 points in the pain score. The treatment with insulin and chitosan gel, brought a pain suppression on the third day, with no reactivation of the pain during the whole study. The application of a film composed of polyurethane and sesame oil with chitosan, brought a reduction in the size of the lesions of 4,54 ± 2,84mm on the 6th day compared with the situation before the beginning of the treatment. The different kinds of laser, which produced a reduction in the pain score just at the beginning of the treatment up to 8,1 ± 1,6 points, and a reduction of the size of the lesions of 4,42 ± 1,02mm on the 7th day. Conclusions: Besides the classic treatments for RAS, we have to take into account other treatment modalities, above all the different kinds of laser. (AU)

Erythromycin: an alternative for the management of oral mucositis?

Background: Oral mucositis (OM) is an important acute adverse effect of anticancer therapy. This condition presents high morbidity and may lead to the suspension of anticancer therapy.Material and Methods: We reviewed the literature on the pathobiology of OM and the properties of erythromycin(EM), to consider the possibility of its use for the prevention and treatment of OM. We searched the PubMed,Scopus and Web of Science databases and selected complete articles published in English or Spanish that met theinclusion criteria. The search terms “erythromycin”, “inflammation”, “immunomodulation” and “oral mucositis”were used.Results: The control of free radicals, transcription factors and pro-inflammatory cytokines has been consideredas the key to the management of OM. EM has the ability to modulate oxidative stress, acts on the transcriptionalsystem and inhibits the production of several cytokines that have been directly implicated in OM pathobiology.Conclusions: The present review suggests that EM could be effective in the treatment of OM. Experimental studies investigating the use of EM in OM should be encouraged. (AU)

Risk factors for oral mucositis during chemotherapy treatmentfor solid tumors: a retrospective STROBE-guided study

Background: This study retrospectively analyzed the risk factors for transchemotherapy oral mucositis (OM).Material and Methods: Before each chemotherapy cycle, patients were routinely evaluated for the presence/severity of OM based on the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale for adverse effectsand graded as follows: However, specific conditions such as mucositis are graded on a five-point scale: 0, absenceof mucositis, grade 1 (Asymptomatic or mild), 2 (Presence of pain and moderate ulceration, without interferencewith food intake), 3 (severe pain with interference with food intake) or 4 (Life-threatening with the need for urgentintervention). Information from 2 years of evaluations was collected and patient medical records were reviewed toobtain data on chemotherapy cycle, sex, age, body mass index, body surface area, primary tumor, chemotherapyprotocol, and history of head and neck radiotherapy. The X² test and multinomial logistic regression were used forstatistical analysis (SPSS 20.0, p<0.05).Results: Among 19,000 total evaluations of 3,529 patients during 5.32±4.7 chemotherapy cycles (CT) the prevalence of OM was 6.3% (n=1,195). Chemotherapy duration (p<0.001), female sex (p=0.001), adjuvant intention(p=0.008) and the use of carboplatin (p=0.001), cisplatin (p=0.029), docetaxel (p<0.001) and bevacizumab(p=0.026) independently increased the risk of mucositis. In head and neck tumors, 2018 year (p=0.017), chemotherapy duration (p=0.018), BMI>30 (p=0.008), radiotherapy (p=0.037) and use of carboplatin (p=0.046) andcyclophosphamide (p=0.010) increased this prevalence.Conclusions: Cycles of chemotherapy, sex, cytotoxicity drugs, bevacizumab and head and neck radiotherapy increase the risk of OM in solid tumors. (AU)

Oral microbiome and systemic antineoplastics in cancer treatment: A systematic review

Background: Oral mucositis is one of the most common side effects in cancer patients receiving systemic antineoplastics. However, the underlying biological mechanisms leading to this condition are still unclear. For this reason, it has been hypothesised that systemic antineoplastics may cause an imbalance on the oral microbiota that subsequently triggers oral mucosa damage. Material and Methods: A systematic review was performed following the PRISMA protocol and the PICO question established was: patients diagnosed with cancer, who are candidates for receiving systemic antineoplastics (P=Patients), that undergo oral microbiome determinations (I=Intervention), before and after systemic antineoplastics administration (C=Comparison), to analyse changes in the oral microbiome composition (O=Outcome). The bibliographic search was carried out in PubMed and other scientific repositories. Results: Out of 166 obtained articles, only 5 met eligibility criteria. Acute myeloid leukaemia (AML) was the most frequent type of cancer (40 %) among the participants. Only one of the studies included a control group of healthy subjects. Heterogeneity in the protocols and approaches of the included studies hindered a detailed comparison of the outcomes. However, it was stated that a decrease in bacteria α diversity is often associated with oral mucositis. On the other hand, fungal diversity was not associated with oral mucositis although α diversity was lower at baseline on patients developing oral candidiasis. Conclusions: There is insufficient scientific evidence of oral microbiological changes in patients undergoing systemic antineoplastics. Further investigations ought to be carried out to identify microorganisms that might play a key role in the pathogenesis of oral mucosa damage in patients undergoing systemic antineoplastics.(AU)

Potencial utilidad de dos presentaciones Triticum vulgare en mucositis oral por quimioterapia en pacientes pediátricos / Potencial utilidade de duas apresentações deTriticum vulgare na mucosite oral devido à quimioterapia em pacientes pediátricos / Potential utility of two presentations of Triticum vulgare in oral mucositis due to chemotherapy in paediatric patients

La mucositis postquimioterapia constituye una complicación severa del manejo antineoplásico, incrementando la estancia hospitalaria y el desarrollo de infecciones invasivas, pudiendo incluso limitar el uso de ciertos fármacos. El interés por medicamentos con menor capacidad de interacción y efectos secundarios ha ido aumentando con el tiempo. Por ello está siendo estudiado un extracto acuoso de trigo (Triticum vulgare) solo o en combinación con caléndula y áloe vera para el tratamiento de mucositis. El objetivo del presente trabajo es describir cuatro casos clínicos de mucositis oral inducida por quimioterapia en pacientes pediátricos tratados con geles de un extracto de trigo, solo o en combinación con áloe vera y caléndula, observándose que influyen positivamente en la evolución de lesiones tempranas. (AU)

A mucosite pós-quimioterapia constitui uma complicação grave do tratamento antineoplásico, aumentando o tempo de internamento e o desenvolvimento de infecções invasivas, podendo até limitar o uso de alguns medicamentos. O interesse por medicamentos com menor capacidade de interação e efeitos secundários tem aumentado ao longo do tempo. Portanto, está a ser estudado um extrato aquoso de trigo (Triticum vulgare), sozinho ou em combinação com calêndula e aloe vera para o tratamento da mucosite. O objetivo do presente trabalho é descrever quatro casos clínicos de mucosite oral induzida por quimioterapia em pacientes pediátricos tratados com géis de um extracto de trigo, isoladamente ou em combinação com aloe vera e calêndula, observando-se que influenciam positivamente na evolução das lesões iniciais. (AU)

Post-chemotherapy mucositis constitutes a severe complication of antineoplastic management, increasing hospitalisation time and the development of invasive infections, and may even limit the use of certain drugs. Interest in drugs with less interactivity and side effects has been increasing over time. Therefore, an aqueous extract of wheat (Triticum vulgare), alone or in combination with calendula and aloe vera, for the treatment of mucositis is being studied. The objective of the present work is to describe four clinical cases of chemotherapy-induced oral mucositis in paediatric patients treated with gels of a wheat extract, alone or in combination with aloe vera and calendula. It was observed that they positively influence the evolution of early lesions. (AU)

Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment

Purpose The objective of this trial was to evaluate the safety and efficacy of melatonin oral gel mouthwashes in the prevention and treatment of oral mucositis (OM) in patients treated with concurrent radiation and systemic treatment for head and neck cancer. Methods Randomized, phase II, double-blind, placebo-controlled trial (1:1 ratio) of 3% melatonin oral gel mouthwashes vs. placebo, during IMRT (total dose ≥ 66 Gy) plus concurrent Q3W cisplatin or cetuximab. Primary endpoint: grade 3–4 OM or Severe Oral Mucositis (SOM) incidence by RTOG, NCI, and a composite RTOG-NCI scales. Secondary endpoints: SOM duration and grade 2–4 OM or Ulcerative Oral Mucositis (UOM) incidence and duration. Results Eighty-four patients were included in the study. Concurrent systemic treatments were cisplatin (n = 54; 64%) or cetuximab (n = 30; 36%). Compared with the placebo arm, RTOG-defined SOM incidence was numerically lower in the 3% melatonin oral gel arm (53 vs. 64%, P = 0.36). In patients treated with cisplatin, assessed by the RTOG-NCI composite scale, both SOM incidence (44 vs. 78%; P = 0.02) and median SOM duration (0 vs. 22 days; P = 0.022) were significantly reduced in the melatonin arm. Median UOM duration assessed by the RTOG-NCI scale was also significantly shorter in the melatonin arm (49 vs. 73 days; P = 0.014). Rate of adverse events and overall response rate were similar between the two arms. Conclusions Treatment with melatonin oral gel showed a consistent trend to lower incidence and shorter SOM duration and shorter duration of UOM. These results warrant further investigation in phase III clinical trial (AU)

Oral mucositis. Is it present in the immunotherapy of the immune checkpoint pd1/pd-l1 against oral cancer? A systematic review / Mucositis bucal. ¿Está presente en la inmunoterapia del punto de control inmunológico pd1/pd-l1 contra el cáncer oral? Una revisión sistemática

Background: Oral mucositis (OM) is a painful lesion that takes place in the mucosa of the oral cavity, usually itsetiology is associated with drug therapies in cancer patients. It is presented as well-defined ulcers whose painfulsymptomatology sometimes implies the suspension of oncological treatment or parenteral feeding, being there-fore an important adverse effect, marking the evolution of these types of therapies against cancer. The presentwork aim is to know the prevalence of oral mucositis in oral cancer immunotherapy compared to its prevalencein standard therapy.Material and Methods: A protocol was developed for a systematic review following PRISMA® guidelines and afocused question (PICO) was constructed. A comprehensive literature search was conducted on electronic data-bases including PubMed, the SCOPUS database, the Cochrane library and the Web of Science (WOS).Results: Six clinical trials were included that met the different inclusion criteria. In these articles, a discrepancybetween the prevalence of OM in patients treated with chemotherapy and patients treated with immunotherapyrelated to the immune checkpoint PD-1/PD-L1 (Nivolumab and Pembrolizumab) was observed. Conclusions: The prevalence of oral mucositis is lower in new immunotherapy with monoclonal antibodies againstoral cancer than drugs used so far (chemotherapy drugs [methotrexate, cisplatin] as well as cetuximab). However,more studies should be carried out to confirm these data.(AU)

The incidence of severe oral mucositis and its occurrence sites in pediatric oncologic patients / La incidencia de la mucositis oral grave y sus lugares de aparición en pacientes oncológicos pediátricos

Background: Childhood cancer is one of the main causes of child mortality and its treatment has debilitatingeffects on the oral cavity. Several oral mucositis (SOM) is one of the most common and may cause undesirablesymptoms such as pain and risk of systemic infection.Material and Methods: This was a longitudinal, retrospective, and observational study determining the incidenceof severe oral mucositis (SOM) and its occurrence sites in pediatric oncologic patients, in João Pessoa, Brazil,between 2013 and 2018. Data from 56 patients aged 1 to 18 years were collected from their medical records andthrough an oral mucosa examination, from the 1st to 5th week of chemotherapy treatment (CT) using the modifiedOral Assessment Guide, by previously calibrated examiners (Kappa index > 0.7). The data were analyzed by theChi-square test, and Odds Ratios were calculated.Results: Most patients were females (54.5%), aged 8.8 years (± 4.8), with hematologic tumors (73.2%), predomi-nantly Acute Lymphoid Leukemia (50.0%). An increase in the occurrence of SOM was observed throughout theCT (P = 0.05), ranging from 12.5% in the 1st to 35.7% in the 5th CT week. In the 1st CT week, there was a predomi-nance of alterations in the lips (5.5%) and saliva (5.5%), while in the 5th , the jugal / palate mucosa (21.4%) remainedthe most affected site by SOM. Differences in the severity of SOM in the jugal / palate mucosa (P = 0.01) and labialmucosa (P = 0.04) were observed over time. In the 5th CT week, the likelihood of developing SOM was 13.3-foldhigher (95% CI: 1.5 - 105.6) in patients with hematologic tumors. Conclusions: The incidence of SOM was higher in the 5th CT week, most commonly affecting the jugal / palate mu-cosa, and patients with hematologic tumors were more prone to develop SOM.(AU)

Efecto de Chamomilla Recutita en el paciente oncológico con mucositis oral: revisión sistemática / Effect of Chamomilla Recutita in the oncology patient with oral mucositis: a systematic review / Efeito da Chamomilla Recutita no paciente oncológico com mucosite oral: revisão sistemática

OBJETIVO: Identificar los efectos de Chamomilla recutita (CR) a través de la literatura nacional e internacional. MÉTODO: Optamos por una revisión sistemática que incluía el análisis riguroso de los artículos, siendo extremadamente confiable y de gran importancia para los investigadores. Los artículos analizados se estudiaron cuidadosamente, de modo que hubo una recopilación de datos sobre los posibles efectos beneficiosos de la planta en cuestión, además del intento de determinar el método y la cantidad necesaria para que se pudiera obtener una aplicación terapéutica correcta en los portadores de este efecto secundario. Al final de la selección de estudios definidos por los criterios establecidos, se aplicaron nuevos instrumentos para validarlos, donde se llegó a una serie de estudios que fueron de máxima relevancia para la presente revisión. RESULTADOS: Con el análisis de los estudios, se encontró CR en forma de enjuagues bucales, pomadas, tinturas e infusiones, todos con diferentes formas de concentración, preparación y uso. Con los análisis realizados, se encontró que la CR tiene un efecto terapéutico potencial en la práctica clínica con pacientes oncológicos y hematológicos, ya que proporciona amplios beneficios para esta población. CONCLUSIÓN: Las formas de usar la CR demostraron ser efectivas, sin embargo, el método de enjuague e infusión fueron los estudios que más demostraron efectos beneficiosos para sus pacientes, a pesar de que todos mostraron efectividad. Se sugiere que los estudios futuros incluyan este método en la práctica clínica de los proveedores de servicios, para beneficiar a sus usuarios

OBJECTIVE: To identify through national and international literature the effects of Chamomilla recutita (CR). METHOD: A systematic review was chosen which included rigorous analysis of articles, being extremely reliable and of great importance for researchers. The articles analyzed were carefully studied in order to collect data on the potential beneficial effects of the plant in question, in addition to the attempt to verify which method and quantity was necessary to obtain a correct therapeutic application in those with this side effect. At the end of the selection of studies defined by the established criteria, new instruments were applied to validate them, where a quantity of researches that were of entire relevance for this review was reached. RESULTS: With the analysis of the studies, CR was found in the form of mouth rinses, ointments, tinctures and infusions, all with different forms of concentration, preparation and use. The analysis showed that CR presents a potential therapeutic effect in clinical practice with oncologic and hematologic patients, because it provides ample benefits to this population. CONCLUSION: The ways of using CR showed to be effective, however, the method of rinsing and infusion were the studies that most demonstrate beneficial effects to their patients, although all showed effectiveness. It is suggested future studies to insert this method in the clinical practice of service providers, in order to benefit its users

OBJETIVO: Identificar através da literatura nacional e internacional os efeitos da Chamomilla recutita (CR). MÉTODO: Optou-se por uma revisão sistemática que incluiu a análise rigorosa de artigos, sendo extremamente confiável e de grande importância para pesquisadores. Os artigos analisados foram criteriosamente estudados, para que houvesse uma coleta de dados sobre os potenciais efeitos benéficos da planta em questão, além da tentativa de constatar qual o método e a quantidade necessária para que se pudesse obter uma correta aplicação terapêutica nos portadores deste efeito colateral. Ao final da seleção dos estudos definidos pelos critérios estabelecidos, aplicou-se novos instrumentos para validação deles, onde se chegou a uma quantidade de pesquisas que eram de inteira relevância para a presente revisão. RESULTADOS: Com a análise dos estudos, foi encontrado a CR em forma de enxaguatórios bucais, pomadas, tinturas e infusões, todas com diferentes formas de concentração, preparação e uso. Constatou-se com as análises realizadas, que a CR apresenta um potencial efeito terapêutico na prática clínica com pacientes oncológicos e hematológicos, pois proporciona amplos benefícios para esta população. CONCLUSÃO: As formas de utilização da CR mostraram-se eficazes, entretanto, o método de enxaguante e infusão foram os estudos que mais demonstram efeitos benéficos aos seus pacientes, apesar de todos demonstrarem eficácia. Sugere-se estudos futuros para que haja inserção deste método na prática clínica dos prestadores de serviços, a fim de beneficiar seus usuários

Patogénesis del dolor en la mucositis oral. Revisión de la literatura / Pathogenesis of pain in oral mucositis. Review of the literature

INTRODUCCIÓN: La mucositis oral es una lesión dolorosa que tiene lugar en la mucosa de la cavidad oral, normalmente su etiología se encuentra asociada a tratamientos farmacológicos en pacientes oncológicos. Se presenta como úlceras bien delimitadas cuya sintomatología dolorosa supone en ocasiones la suspensión del tratamiento oncológico o la alimentación por vía parenteral, siendo por tanto un efecto adverso importante, marcando el devenir en este tipo de terapias contra el cáncer. OBJETIVO: El objetivo del presente artículo es poner en relieve cómo se produce el dolor en esta patología que acontece en la mucosa de la cavidad oral. DISCUSIÓN: La mucositis oral se va a presentar tras una cascada de eventos biológicos que implican diferentes procesos moleculares tras el tratamiento con quimioterapia o radioterapia. El dolor en la mucositis oral puede poseer un componente inflamatorio y también un componente neuropático. En su fisiopatología, el dolor va a estar mediado por diferentes familias de receptores y factores. CONCLUSIÓN: La mucositis oral presenta un gran componente doloroso asociado, en el que cobran especial protagonismo en su aparición, las familias de los receptores y factores TRP, ET-1, TNF y ROS, entre otros. El conocimiento de la patogénesis del dolor en esta patología permitirá desarrollar terapéuticas contra el dolor en estudios futuros

INTRODUCTION: Oral mucositis is a painful lesion that occurs in the mucosa of the oral cavity. Its aetiology is usually associated with drug treatments in cancer patients. It presents as well-defined ulcers whose painful symptoms sometimes lead to the suspension of cancer treatment or parenteral nutrition. They therefore represent a significant adverse effect that marks the future in this type of cancer therapy. OBJECTIVE: The objective of this article is to highlight how pain occurs in this pathology that takes place in the mucosa of the oral cavity. DISCUSSION: Oral mucositis will occur following a cascade of biological events involving different molecular processes following treatment with chemotherapy or radiotherapy. Pain in oral mucositis may have an inflammatory component as well as a neuropathic component. In its pathophysiology, pain will be mediated by different families of receptors and factors. CONCLUSION: Oral mucositis has a large associated painful component, in which the families of TRP, ET-1, TNF and ROS receptors and factors, among others, play a major role in its appearance. Knowledge of the pathogenesis of the pain in this pathology will allow pain therapies to be developed in future studies

Eficacia y seguridad de una nueva formulación de enjuague bucal de dexametasona para el manejo de la estomatitis en pacientes con cáncer / Effectiveness and safety of a novel dexamethasone mouthwash formulation in managing stomatitis in cancer patients

OBJETIVO: Describir una nueva formulación de enjuague bucal con dexametasona y analizar su efectividad y seguridad en pacientes que reciben agentes antineoplásicos que producen estomatitis. MÉTODO: Estudio observacional prospectivo realizado en un hospital universitario entre marzo de 2017 y noviembre de 2019. Se incluyeron los pacientes que iniciaron everolimus. El tratamiento consistió en enjuagar con solución oral de dexametasona dos veces al día hasta la interrupción del tratamiento con everolimus. Se reclutó una segunda cohorte de pacientes con estomatitis inducida por otros agentes antineoplásicos con alta probabilidad de provocar estomatitis. Se evaluó la efectividad y seguridad del enjuague bucal con dexametasona. RESULTADOS: Se reclutaron nueve pacientes en profilaxis con formulación de enjuague bucal con dexametasona; seis pacientes presentaban un diagnóstico de cáncer de mama, dos de tumor neuroendocrino y uno de carcinoma renal. Cuatro pacientes desarrollaron estomatitis leve (grado 1-2) y tres pacientes descontinuaron everolimus por otros eventos adversos relacionados con el tratamiento. Se prescribió enjuague bucal con dexametasona en cinco pacientes con estomatitis existente como tratamiento. Todos los pacientes lograron una reducción significativa de la gravedad de la estomatitis tras iniciar el enjuague bucal con dexametasona. En general, el nuevo enjuague bucal con dexametasona fue bien tolerado y no se requirieron reducción de dosis ni interrupción debido a estomatitis. CONCLUSIONES: La nueva formulación de enjuague bucal con dexametasona podría considerarse una alternativa adecuada para el manejo de la estomatitis

OBJECTIVE: To present a new dexamethasone mouthwash formulation and analyze its effectiveness and safety among patients receiving stomatitis-producing antineoplastic agents. METHOD: Prospective observational study conducted in a university hospital between March 2017 and November 2019. Consecutive patients starting everolimus were enrolled. Patients were instructed to rinse dexamethasone mouthwash formulation twice daily until discontinuation of everolimus. A second cohort of patients with existing stomatitis induced by high probability of producing stomatitis chemotherapy therapies was also recruited to assess treatment effectiveness. Effectiveness and safety of dexamethasone mouthwash formulation was assessed. RESULTS: Dexamethasone mouthwash formulation was prescribed in nine patients as prophylaxis. Six patients were diagnosed with breast cancer, two with neuroendocrine tumor and one with renal cell carcinoma. Four patients developed mild stomatitis (grade 1-2) and three patients discontinued everolimus due to other treatment-related adverse events. In addition, dexamethasone mouthwash formulation was prescribed as treatment in five patients with existing stomatitis. All patients achieved a significant reduction in the severity of stomatitis after starting the dexamethasone mouthwash formulation. In both cohorts, dexamethasone mouthwash formulation was well tolerated and neither dose reduction nor discontinuation related to stomatitis was required. CONCLUSIONS: Dexamethasone mouthwash formulation could be considered as a suitable alternative for stomatitis management

Effect of zinc on oropharyngeal mucositis in children with acute leukemia undergoing chemotherapy

BACKGROUND: Oropharyngeal mucositis (OM) is one of the main side-effects of oncological therapy. There is no treatment to prevent its occurrence, but some zinc-based therapies have been proven to help in decreasing its in-tensity. The objective of this study was to determine the effect of zinc in OM in children with acute leukemia in the early stages of oncological treatment. MATERIAL AND METHODS: This quasi-experimental study evaluated OM in 2 groups (control group: conventional hospital management, and experimental group: administration of 50 mg of zinc gluconate daily plus conventional hospital management). OM severity was recorded at a two-month follow-up. RESULTS: Forty-nine patients (26 in the control group and 23 in the experimental group) were included. The mean age of the patients was 11.1 ± 2.7 years; 65.3% had a diagnosis of pre-B acute lymphoblastic leukemia. The incidences of OM in the control group and the experimental group were 46.2% and 26.1%, respectively, but the difference was not significant. Based on a negative binomial regression model, females had, on average, 1.5 more days with OM (p = 0.002), and patients assigned to the experimental group had, on average, 2 less days with OM than the control group (p = 0.001). The pain score was higher in the control group (p = 0.0009), as was the mean score on the WHO scale (p = 0.0012). CONCLUSIONS: Zinc facilitated a reduction in the severity and duration of OM; further studies focusing on children are needed to confirm the effects of this trace element

No disponible

Does chlorhexidine improve outcomes in non-surgical management of peri-implant mucositis or peri-implantitis?: a systematic review and meta-analysis

BACKGROUND: With greater number of implants being placed in clinical practice, incidence of peri-implant diseases are on the rise. It is not known whether chlorhexidine (CHX) improves outcomes in the management of peri-implant diseases. The aim of this systematic review and meta-analysis was to evaluate the role of CHX in improving outcomes with non-surgical management of peri-implant mucositis and periimplantitis. MATERIAL AND METHODS: An electronic search of PubMed, Scopus, Embase, and CENTRAL (Cochrane Central Register of Controlled Trials) databases up to 1st August 2019 was carried out to search for studies evaluating the efficacy of CHX for non-surgical management of peri-implant diseases. RESULTS: Seven studies were included. Four studies evaluated the role of CHX in peri-implant mucositis and three in peri-implantitis. Oral prophylaxis with mechanical cleansing of implant surface prior to CHX use was carried out in all seven studies. Meta-analysis indicated that use of CHX did not improve probing depths in peri-implant mucositis (SMD = 0.11; 95% CI: -0.16 to 0.38; p = 0.42, I2= 0%). Similarly, CHX did not significantly reduce probing depths in patients with peri-implantitis (MD= 1.57; 95% CI: -0.88 to 4.0; p = 0.21, I2 = 98%). Results on the efficacy of CHX in reducing BOP in peri-implantitis are conflicting. CONCLUSIONS: Results of our study indicate that adjunctive therapy with CHX may not improve outcomes with non-surgical management of periimplant mucositis. Conclusions with regards to its role in non-surgical management of periimplantitis cannot be drawn. There is a need for more homogenous RCTs with large sample size to define the role of CHX in non-surgical management of peri-implant mucositis and peri-implantitis

No disponible

Manejo y consideraciones clínicas de la enfermedad inflamatoria intestinal en la consulta dental / Management and clinical considerations of the inflammatory bowel disease in the dental office

El objetivo de este trabajo es realizar una revisión bibliográfica sobre la enfermedad inflamatoria intestinal (EII) y sus manifestaciones clínicas orales. La EII es un término que abarca dos enfermedades idiopáticas del tracto gastrointestinal: la colitis ulcerosa y la enfermedad de Crohn. Cuando un paciente que tiene una de estas condiciones se presenta para el tratamiento en nuestra consulta dental, es necesario ser consciente de la condición del paciente, controlar los síntomas indicativos de enfermedad inicial o recaída, y haber realizado una correcta historia clínica que incluya los fármacos que interactúan con medicamentos gastrointestinales o que pueden agravar la situación del paciente. Además, las manifestaciones orales de la enfermedad gastrointestinal no son infrecuentes, por lo que el dentista también debe estar familiarizado con los patrones orales de la enfermedad

The objective was to perform a literature review of the inflammatory bowel disease (IBD) and it's clinical oral manifestations. It is a term that encompasses two idiopathic diseases of the gastrointestinal tract: ulcerative colitis and Crohn’s disease. When a patient who has one of these conditions comes for treatment at our dental office, it is necessary to be aware of the patient's condition, to control the symptoms indicative of initial illness or relapse, and to have a correct medical history including the drugs which interact with gastrointestinal drugs or which may aggravate the patient's condition. In addition, oral manifestations of gastrointestinal disease are not infrequent, so the dentist should also be familiar with the oral patterns of the disease

Chewing gum is more effective than saline-solution gargling for reducing oral mucositis

Objective: This quasi-experimental study compared the effectiveness of chewing gum and gargling with a saline solution as two types of intervention to reduce oral mucositis scores. Method: The sample consisted of 44 children who were divided into two groups, one of which chewed gum, and the other gargled with a saline solution. The Mann-Whitney U test was used to analyze the data. Results: There was a significant difference (p = 0.001) in post-intervention oral-mucositis scores. The significant mean difference between the groups indicated that the decreased oral mucositis scores for the chewing gum group was more substantial than for the group gargling with a saline solution (p = 0.001). Conclusions: The data showed that chewing gum is more effective than gargling with a saline solution, and it can be incorporated into the nursing protocol for treating pediatric cancer patients

No disponible

Manejo de las infecciones odontogénicas en las consultas de atención primaria: ¿antibiótico? / Management of odontogenic infections in Primary Care: Antibiotic?

Nuestro objetivo es intentar contribuir al uso racional de los antibióticos prescritos por los médicos de familia cuando un paciente consulta por un problema odontológico. Actualmente la pregunta que nos debemos hacer es si hay que tomar antibiótico, en lugar de cuál dar. Revisamos las principales infecciones odontológicas, cuál debe ser el tratamiento adecuado y el papel de la prevención. Es necesario conocer la complejidad de la microflora de la cavidad oral, pues de ella dependerá la conveniencia de antibioterapia, la evolución hacia la curación o la progresión de algunas infecciones odontogénicas. La placa bacteriana, formada por el biofilm, se comporta como una barrera para la acción de los antimicrobianos. Es en la prevención de su formación, así como en la eliminación mecánica de esta una vez formada, en lo que el médico de familia debe insistir. Debemos transmitir a la población que los antibióticos no curan el dolor dental

Our aim is to contribute to the rational use of antibiotics prescribed by family doctors when a patient consults for a dental problem. Nowadays we should not ask which antibiotic to give. The question has to be if we need to prescribe antibiotics in front of the most common odontogenic infections seen in our practice. We review the main dental infections, which should be their appropriate management and the role of prevention. We need to know the complexity of the oral microbiome because it’l depend on the appropriateness of the antibiotherapy, the evolution towards cure or progression of some odontogenic infections. The bacterial plaque, formed by the biofilm, behaves as a barrier to the action of antimicrobials. It’s in the prevention of its development as well as in it mechanical elimination once shaped, in what the family doctor should insist. We must transmit antibiotics don’t heal dental pain

Fentanyl pectin nasal spray for painful mucositis in head and neck cancers during intensity-modulated radiation therapy with or without chemotherapy

Purpose. The aim of the current analysis was to evaluate the effectiveness and tolerability of rapid onset opioid in a cohort of head and neck cancer (HNC) patients affected by painful mucositis influencing swallowing function during RT ± ChT with definitive or adjuvant intent. Methods. A retrospective analysis was conduct on HNC patients during RT ± ChT that received fentanyl pectin na sal spray (FPNS) for incidental BTP due to painful mucositis 13 min before the main meals. The period of observation has been 90 days starting from the beginning of RT ± ChT. Results. Forty HNC patients with incidental BTP due to painful mucositis treated with FPNS were analyzed. The mean NRS of untreated episodes of BTP was 5.73 ± 1.54 decreasing to 2.25 ± 2.45 with FPNS (median dose 100 mcg). During the pain treatment, the number of meals increased from 2.08 ± 0.35 to 2.868 ± 0.4 (p = 0.000), and the BMI remained stable (from 25.086 ± 3.292 to 25.034 ± 3.090; p = 0.448). The 94.9% of patients was satisfied or very satisfied for the rapidity of the effect, and 97.4% for the easiness and convenience in the use. Conclusions. FPNS showed an acceptable safety activity profile in predictable BTP due to painful mucositis in HNC patients during RT ± ChT. FPNS was also effective in reducing the mucositis sequelae and allowing the completion of RT scheduled scheme. Moreover, patients declared satisfaction in terms of ease of use (AU)

No disponible